Phase 3
N=73
Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients
Gastrointestinal Cancer · Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00513357 ↗Enrolled (actual)
73
Serious AEs
5.5%
Results posted
Sep 2012
Primary outcome: Primary: Change in Appetite as Measured by ESAS — -0.83; -1.19 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Melatonin (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- M.D. Anderson Cancer Center
- Primary completion
- Dec 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Appetite as Measured by ESAS |
-0.83; -1.19 | — |
Summary
The goal of this clinical research study is to evaluate the effectiveness of melatonin for the management of poor appetite and weight loss in advanced cancer patients. The effectiveness of melatonin on weight gain, keeping/gaining of lean muscle mass, improved appetite, and side effects will also be evaluated.
Eligibility Criteria
Inclusion Criteria
- Patients with solid gastrointestinal tumors or lung cancer patients referred to palliative care and a 5% or more involuntary weight loss within the last 6 months with anorexia (>3 on visual analog scale such as ESAS)
- Greater than or equal to 18 years of age
- Karnofsky score of 40 or higher
- Patient has the ability to maintain oral food intake during the study period
- If patients who have persistent anorexia/cachexia and are currently taking Megace, corticosteroids, non-steroidal anti-inflammatories (NSAID's), or thalidomide, they should be on the medication at least 2 weeks prior to study inclusion
- Ability to sign informed consent and understand study procedures
- Patient can continue all medications including complementary therapies or antineoplastic therapy while on-study other than melatonin if they have been on stable dose for at least 2 weeks
- Negative pregnancy testing in women with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.
- Patients who cannot take Megace because of past history or elevated risk of DVT, adrenal insufficiency, impotence, hyperglycemia, CHF, menorrhagia, etc.
- Patients who have persistent anorexia/cachexia after treatment with Megace has failed
Exclusion Criteria
- Patients who have dementia or delirium on entry into study as determined by the palliative care specialist using DSM-IV-criteria
- Patients who are currently taking melatonin
- Inability to take oral food during the study period
- Unstable secondary cachexia caused by nausea, diarrhea, taste abnormalities, mucositis, constipation, dysphagia, or clinical depression prior to study inclusion. These symptoms should be resolved or stable for >/= 2 weeks at the time of inclusion into study as determined by the Palliative Care Specialist.
- Inability to sign informed consent or understand study procedures
- Karnofsky score of /= 10 mcL/mL at baseline will be excluded
- Pregnant females or females who are lactating/nursing
Data sourced from ClinicalTrials.gov (NCT00513357). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.